Evidence map›Paper›PMID 42630712›Full record

Trial reportOncology research2026

A Phase II Clinical Trial of Chemotherapy Rechallenge with or without Targeted Therapy in Refractory Metastatic Colorectal Cancer.

Chenchen Wang, Mingzhu Huang, Wenhua Li, Xuedan Sheng, Xiaoying Zhao, Xiaodong Zhu, Zhiyu Chen, Zhe Zhang, Haiming Li, Weijian Guo

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chenchen WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Mingzhu HuangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenhua LiDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xuedan ShengDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoying ZhaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaodong ZhuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhiyu ChenDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhe ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Haiming LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Weijian GuoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsAdultAgedBevacizumabCetuximabDrug Resistance, NeoplasmFemaleHumansIrinotecanMaleMiddle AgedMolecular Targeted TherapyNeoplasm MetastasisOxaliplatinQuinazolinesBevacizumabCetuximabIrinotecanOxaliplatinQuinazolinesraltitrexedThiophenesclinical trialColorectal cancerrechallenge therapyrefractory disease

Identifiers

PMID42630712
PMCPMC13494499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.